Kidney Week 2023
Summaries from Kidney Week 2023, held from November 1 – 5, 2023.
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
With: Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN
Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN from Cleveland Clinic review early session: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome in Children and Adults: Diagnosis and Treatment, presented at Kidney Week 2023.
Membranoproliferative Glomerulonephritis and C3 Glomerulopathy
With: Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN
Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN from Cleveland Clinic review early session: Membranoproliferative Glomerulonephritis and C3 Glomerulopathy, presented at Kidney Week 2023.
IgA Nephropathy
With: Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN
Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN from Cleveland Clinic review early session: IgA Nephropathy, presented at Kidney Week 2023.
Nephrology Is Finally Getting US Food and Drug Administration Approvals for Rare Glomerular Disease Medications
With: Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN
Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN from Cleveland Clinic review early session: Accelerated Approval: How Nephrology Is Finally Getting US Food and Drug Administration Approvals for Rare Glomerular Disease Medications and What It Means, presented at Kidney Week 2023.
Glomerular Disease in Pregnancy
With: Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN
Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN from Cleveland Clinic review early session: Glomerular Disease in Pregnancy, presented at Kidney Week 2023.
Long-term outcomes comparing belatacept- vs tacrolimus-based maintenance immunosuppression in kidney transplant recipients: A UNOS database analysis
Presenter: Adriana Montalvan, MD, Beth Israel Deaconess Medical Center, Boston, MA.
While rates of death and death-censored graft failure were higher in patients receiving belatacept than with tacrolimus, those discharged on belatacept had a higher comorbid burden.
Improvement in serum creatinine was associated with favorable clinical outcomes in patients with hepatorenal syndrome: A post hoc analysis of the CONFIRM study
Presenter: Juan Carlos Q. Velez, MD, Ochsner Health, New Orleans, LA.
The reduction in serum creatinine levels associated with terlipressin treatment improves multiple clinical outcomes among patients with hepatorenal syndrome.
Plasma metabolites can predict cardiorenal outcomes in patients with type 2 diabetes and high cardiovascular risk
Presenter: Michael K. Hansen, Janssen Research and Development, Spring House, PA.
Higher levels of some baseline metabolites, especially xanthosine, are predictive of adverse cardiorenal outcomes in patients with type 2 diabetes and high cardiovascular risk.
Multiple daily doses of oral iron supplementation best for improving hemoglobin levels in anemia and chronic kidney disease
Presenter: Nilang G. Patel, MD, Virginia Commonwealth University, Richmond, VA
A strategy using multiple daily doses of oral iron supplements provided greater improvements in hemoglobin and iron indices than daily dosing or alternate-day doses in patients with iron deficiency anemia and chronic kidney disease.